BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 38362864)

  • 1. The role of the microbiome in liver disease.
    Schöler D; Schnabl B
    Curr Opin Gastroenterol; 2024 May; 40(3):134-142. PubMed ID: 38362864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Benedé-Ubieto R; Cubero FJ; Nevzorova YA
    Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promises of microbiome-based therapies.
    Bajaj JS; Ng SC; Schnabl B
    J Hepatol; 2022 Jun; 76(6):1379-1391. PubMed ID: 35589257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease.
    Ranjbarian T; Schnabl B
    Semin Liver Dis; 2023 Aug; 43(3):311-322. PubMed ID: 37527781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiome as a therapeutic target in alcohol-related liver disease.
    Sarin SK; Pande A; Schnabl B
    J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
    Hong M; Han DH; Hong J; Kim DJ; Suk KT
    Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
    J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
    Das BK
    APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
    Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
    Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
    Leclercq S; de Timary P; Stärkel P
    Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.
    Koning M; Herrema H; Nieuwdorp M; Meijnikman AS
    Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.
    Hyun JY; Kim SK; Yoon SJ; Lee SB; Jeong JJ; Gupta H; Sharma SP; Oh KK; Won SM; Kwon GH; Cha MG; Kim DJ; Ganesan R; Suk KT
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alcohol or Gut Microbiota: Who Is the Guilty?
    Meroni M; Longo M; Dongiovanni P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease: Molecular mechanisms, biomarkers, and therapeutic prospective.
    Zafari N; Velayati M; Fahim M; Maftouh M; Pourali G; Khazaei M; Nassiri M; Hassanian SM; Ghayour-Mobarhan M; Ferns GA; Kiani MA; Avan A
    Life Sci; 2022 Sep; 305():120760. PubMed ID: 35787997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiota, Liver Diseases, and Alcohol.
    Cassard AM; Gérard P; Perlemuter G
    Microbiol Spectr; 2017 Aug; 5(4):. PubMed ID: 28840806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiota, a key player in alcoholic liver disease.
    Cassard AM; Ciocan D
    Clin Mol Hepatol; 2018 Jun; 24(2):100-107. PubMed ID: 29268595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiota-based treatments in alcoholic liver disease.
    Sung H; Kim SW; Hong M; Suk KT
    World J Gastroenterol; 2016 Aug; 22(29):6673-82. PubMed ID: 27547010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.
    Chu H; Duan Y; Lang S; Jiang L; Wang Y; Llorente C; Liu J; Mogavero S; Bosques-Padilla F; Abraldes JG; Vargas V; Tu XM; Yang L; Hou X; Hube B; Stärkel P; Schnabl B
    J Hepatol; 2020 Mar; 72(3):391-400. PubMed ID: 31606552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.